Want to see TRVI full AI Analyst Report?
TRVI Stock Chart & Stats
$13.47
<$0.01(0.12%)
At close: 4:00 PM EST
$13.47
<$0.01(0.12%)
Day’s Range― - ―
52-Week Range$5.93 - $20.15
Previous CloseN/A
Volume226.18K
Average Volume (3M)2.56M
Market Cap
$2.64B
Enterprise Value$2.31B
Total Cash (Recent Filing)$171.78M
Total Debt (Recent Filing)$682.00K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding141,979,700
10 Day Avg. Volume1,820,513
30 Day Avg. Volume2,561,308
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)9.91
Price to Sales (P/S)0.00
P/FCF Ratio-43.15
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-67.81K
Enterprise Value/Ebitda-50.62
Forecast
1Y Price Target
$24.43Price Target Upside81.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash Runway & Low LeveragePro forma liquidity into 2030 and minimal debt provide a durable funding cushion to advance multiple pivotal trials and regulatory interactions. This reduces near-term financing pressure, enabling execution on planned Phase III/IPF and Phase IIb programs without immediate dilution risk, supporting 2–6 month strategic focus.
Robust Intellectual PropertyIssued core patents through 2039, plus pending U.S. filings that could extend to 2046, create a meaningful exclusivity window for Haduvio. Durable IP protection underpins long-term commercial potential and incentivizes partner interest, helping preserve pricing power and return prospects if clinical and regulatory milestones are met.
Regulatory Alignment & Defined Trial PathConstructive FDA engagement and finalized Phase III protocols materially lower regulatory uncertainty for the IPF indication. Near-term trial initiations create clear, executable milestones and potential value inflection points, strengthening the company's operational roadmap and focusing resources on de-risking approval pathways over the medium term.
Bears Say
Pre-revenue With Persistent LossesAbsence of commercial revenue means value is fully contingent on clinical and regulatory success. Persistent net losses reduce operating flexibility and heighten dependence on external capital; over a 2–6 month horizon this keeps dilution and funding availability as central risks if trial setbacks or higher-than-expected costs occur.
Material Cash Burn Despite ImprovementNegative operating and free cash flow indicate recurring funding needs even with recent financing. While FCF improved, ongoing burn will necessitate future capital to support trials, commercial preparation, or trial upsizing. This structural cash deficit elevates dilution risk and constrains strategic optionality over coming quarters.
Trial Upsizing & Regulatory Execution RiskSample-size re-estimation (SSRE) and adaptive designs create realistic upside for cost and timing if conditional power is low. Such structural execution risk can materially extend timelines and cash requirements, complicating planning and potentially forcing additional financings or strategic trade-offs if interim results trigger upsizing.
Trevi Therapeutics News
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $5.93 and its highest was $20.15 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $2.64B.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 28 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on May 05, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.076 by -$0.014.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.11.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 141,979,700 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.076. Following the earnings report the stock price went down -2.729%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Currently, no hedge funds are holding shares in TRVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Trevi Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.43 (81.36% Upside)
$24.43 (81.36% Upside)
Hedge Fund Trend
Increased
By 326.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
232.05%
12-Months-Change
Fundamentals
Return on Equity
-24.53%
Trailing 12-Months
Asset Growth
67.85%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
TRVI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid execution progress: a strengthened balance sheet (pro forma cash ~ $334M) with runway into 2030, positive FDA alignment for IPF-related chronic cough, near-term trial initiations (Phase III IPF, Phase IIb RCC), an adaptive plan for non-IPF-ILD pending FDA agreement, expansion of IP filings and active scientific visibility (ATS, Investor Day). Principal risks discussed include competitor P2X3 readouts, possible trial upsizing via SSRE (and associated costs/timing), placebo variability in RCC, and regulatory dependence for the non-IPF-ILD program. On balance, the company presented multiple material positives and manageable risks tied to execution and external competitive/regulatory factors.View all TRVI earnings summariesTRVI Stock 12 Month Forecast
Average Price Target
$24.43
▲(81.36% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
1.32% Insiders
16.81% Mutual Funds
2.02% Other Institutional Investors
69.76% Public Companies and
Individual Investors